---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002752"
form_type: "8-K"
ticker: "OBIO"
cik: "0001814114"
company_name: "Orchestra BioMed Holdings, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:45.737695+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure

## Summary
- Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.
- Remaining up to $10M from future revenue earnouts based on milestone achievement.
- Vivasure's PerQseal Elite received CE Mark and filed PMA with FDA; 0% major complications at 30 days.
- Haemonetics closed acquisition on January 9, 2026; OBIO was strategic holder since formation.

## SEC filing metadata
- accession: 0001104659-26-002752
- form_type: 8-K
- ticker: OBIO
- cik: 0001814114
- company_name: Orchestra BioMed Holdings, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/0001104659-26-002752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/tm262832d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002752
- JSON: https://secwatch.observer/filing/0001104659-26-002752.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.